Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE versus MEDIHALER ERGOTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE versus MEDIHALER ERGOTAMINE.
HYDERGINE vs MEDIHALER ERGOTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (Hydergine) are a mixture of dihydrogenated ergot alkaloids that act as non-selective dopamine D1 and D2 receptor agonists and serotonin receptor antagonists. They enhance cerebral blood flow and neuronal metabolism, and modulate neurotransmitter activity.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist with additional affinity for 5-HT2, dopamine D2, and alpha-adrenergic receptors. It causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation.
1-2 mg orally three times daily.
One inhalation (0.36 mg ergotamine) at onset of migraine; may repeat after 5 minutes if needed, up to 6 inhalations per attack and 15 per week.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, steady-state is achieved within 3-5 days.
The terminal elimination half-life is approximately 2 hours for the initial phase, followed by a prolonged terminal phase of 21-30 hours due to slow release from tissue binding sites. This long terminal half-life contributes to the risk of accumulation and toxicity with frequent dosing.
Primarily fecal (80%) via biliary excretion; renal excretion accounts for <10% of unchanged drug.
Ergotamine is extensively metabolized in the liver. Approximately 90% of the dose is excreted as metabolites in the bile/feces, with less than 3% excreted unchanged in urine.
Category C
Category D/X
Ergot Alkaloid
Ergot Alkaloid